<code id='D5877B2045'></code><style id='D5877B2045'></style>
    • <acronym id='D5877B2045'></acronym>
      <center id='D5877B2045'><center id='D5877B2045'><tfoot id='D5877B2045'></tfoot></center><abbr id='D5877B2045'><dir id='D5877B2045'><tfoot id='D5877B2045'></tfoot><noframes id='D5877B2045'>

    • <optgroup id='D5877B2045'><strike id='D5877B2045'><sup id='D5877B2045'></sup></strike><code id='D5877B2045'></code></optgroup>
        1. <b id='D5877B2045'><label id='D5877B2045'><select id='D5877B2045'><dt id='D5877B2045'><span id='D5877B2045'></span></dt></select></label></b><u id='D5877B2045'></u>
          <i id='D5877B2045'><strike id='D5877B2045'><tt id='D5877B2045'><pre id='D5877B2045'></pre></tt></strike></i>

          hotspot

          hotspot

          author:knowledge    Page View:13945
          James Comer -- coverage from STAT
          Rep. James Comer, chair of the House Oversight Committee Kevin Dietsch/Getty Images

          WASHINGTON — Congress wants to reform PBM business practices to help lower the cost of medicines — but don’t think they’ve forgotten drugmakers have a role in high drug prices.

          Two lawmakers, including a Republican, questioned PhRMA Chief Operating Officer Lori Reilly about just how much her group was spending on its major campaigns against PBMs this year. Both Reps. Summer Lee (D-Pa.) and Eric Burlison (R-Mo.) used their time to question drugmakers over their spending on lawsuits against Medicare drug price negotiation and ad campaigns against pharmacy benefit managers.

          advertisement

          Although Lee started off bashing PBMs for the fees they charge drugmakers, she quickly aimed her fire back on pharma. She said brand drugmakers charge Americans double what they charge other countries, and she asked why several drugmakers are suing the federal government over Medicare’s drug price negotiation.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          The explosion of genetic testing requires a new approach
          The explosion of genetic testing requires a new approach

          AtechnicianplacesanarraycontainingDNAinformationinascanner.GREGBAKER/AFPviaGettyImagesNewtechnologyh

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Will biotech layoffs continue through 2023?

          KaraColuccio,amanagingpartneratPerspectiveGroup,saysthejobmarketforbiotechexecutiveshasgottenmuchtig